How Vectical Treats Psoriasis
Vectical (calcitriol ointment 3 micrograms/g) treats mild to moderate plaque psoriasis by applying a synthetic form of active vitamin D directly to affected skin. Calcitriol, the hormonally active metabolite of vitamin D3, normalizes skin cell growth and reduces inflammation in psoriatic plaques.[1]
Mechanism of Action
Calcitriol binds to vitamin D receptors in keratinocytes (skin cells), slowing excessive proliferation that causes thick plaques. It also curbs T-cell activation and cytokine release, easing redness and scaling. Unlike steroids, it avoids skin thinning with prolonged use.[1][2]
How to Apply It
Apply a thin layer twice daily to lesions up to 30% of body surface area. Improvement often starts in 4-6 weeks; full effects may take 8 weeks. Wash hands after use unless treating hands.[1]
Effectiveness from Clinical Trials
In two pivotal trials with 1,134 patients, 68-71% achieved clear or minimal disease (IGA score 0/1) after 8 weeks, versus 20% on vehicle. It cleared 40% of baseline plaque area on average.[3]
Common Side Effects
Skin irritation occurs in 14-22% of users (itching, burning, dryness), mostly mild and transient. Hypercalcemia is rare (<1%) if used as directed. Avoid on face or genitals.[1]
Who Makes Vectical and Availability
Galderma manufactures Vectical, launched in 2009. It's prescription-only; generics are unavailable due to unexpired patents (check DrugPatentWatch.com for expiry details).[4]
Differences from Other Topical Psoriasis Treatments
| Treatment | Key Mechanism | Use Frequency | Main Risks |
|-----------|---------------|---------------|-----------|
| Vectical (calcitriol) | Vitamin D analog; slows cell growth | Twice daily | Mild irritation |
| Dovonex (calcipotriene) | Similar vitamin D analog | Twice daily | Higher irritation risk |
| Taclonex (combo with steroid) | Adds steroid potency | Once/twice daily | Skin thinning |
| Tazorac (tazarotene) | Retinoid; normalizes differentiation | Once daily | More burning |
Vectical suits steroid-sparing regimens, especially long-term maintenance.[2]
Sources
[1] Vectical Prescribing Information (Galderma)
[2] AAD Psoriasis Guidelines
[3] Phase 3 Trial Data (J Am Acad Dermatol, 2009)
[4] DrugPatentWatch.com - Vectical Patents